Apomorphine Effects on Pain in Parkinson's Disease
Trial
Phase 2
Unknown
May 17, 2022
Smart Home-based Technology to Promote Functional Mobility Among Individuals With Parkinson's Disease
Trial
N/A
Unknown
May 16, 2022
Effects of Complementary Therapies in People With Mild to Moderate Parkinson's Disease
Trial
N/A
Completed
May 16, 2022
A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria
Trial
N/A
Completed
May 16, 2022
Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease
Trial
Phase 2
Unknown
May 16, 2022
A Pilot Study of Terazosin for Parkinson's Disease
Trial
Phase 1
Completed
May 15, 2022
Innovative Biomarkers in de Novo Parkinson's Disease
Trial
N/A
Terminated
May 11, 2022
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
Trial
Phase 2
Completed
May 10, 2022
In-Home Care for Patients With Parkinson's Disease
Trial
N/A
Completed
May 10, 2022
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Trial
Phase 2
Completed
May 8, 2022
Measuring Parkinson's Disease With Tear Fluid
Trial
N/A
Completed
May 8, 2022
Prospective Memory in Parkinson's Disease
Trial
N/A
Completed
May 5, 2022
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
Trial
N/A
Completed
May 3, 2022
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Trial
N/A
Completed
May 3, 2022
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
Trial
Phase 1
Terminated
May 2, 2022
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Trial
Phase 2
Completed
May 2, 2022
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease
Trial
Phase 1
Terminated
May 2, 2022
tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease
Trial
N/A
Unknown
May 1, 2022
Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease
Trial
Phase 4
Unknown
May 1, 2022
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Trial
Phase 2
Completed
April 28, 2022